GlassScriptPhysician profile
Kali Hammonds
NPI 1528637022
$3,053.88
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.46 · 2022: $780 · 2023: $1,718 · 2024: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409 · Travel and Lodging: $806 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.93 |
| Travel and Lodging | $806.47 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,271.42 | 2022-2024 | Interstim, Truclear |
| Abbvie INC. | $423.07 | 2022-2024 | |
| Astellas Pharma US INC | $199.95 | 2022-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $151.46 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.67 | 2022-2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $98.85 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $89.94 | 2023-2024 | |
| Millicent US INC | $62.50 | 2023-2024 | Intrarosa, Femring |
| Lilly USA, LLC | $50.61 | 2022 | |
| Merck Sharp & Dohme LLC | $46.58 | 2022-2023 | Gardasil 9 |
| Axonics, INC. | $45.82 | 2023 | Bulkamid |
| Urovant Sciences INC | $44.47 | 2022 | |
| Novo Nordisk INC | $43.48 | 2022 | |
| Pfizer INC. | $41.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.38 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $33.62 | 2022 | |
| Exeltis, USA INC. | $31.33 | 2024 | Slynd |
| Sanofi-Aventis U.S. LLC | $30.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.42 | 2022 | |
| Hologic Sales and Service, LLC | $21.62 | 2024 | Aptima, Thinprep 2000 Processor |
| Dynavax Technologies Corporation | $19.62 | 2022 | |
| Kerecis Limited | $19.36 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Novartis Pharmaceuticals Corporation | $18.88 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.61 | 2022 | |
| Sage Therapeutics, LLC | $14.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2022 | |
| Amarin Pharma, INC. | $13.50 | 2022 | |
| Scynexis, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kali Hammonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.